Rocket Lab (Rocket Lab (RKLB)) shares took a hit Thursday as investors digested the company's plan to potentially sell up to $3 billion worth of common stock. The offering, filed late Wednesday, raises the usual questions about dilution — but in this case, it's happening against a backdrop of massive industry excitement, thanks to SpaceX's long-awaited IPO filing.

Let's break down what's going on.

The $3 Billion Question

Rocket Lab filed a prospectus supplement for an equity distribution agreement that allows it to offer and sell up to $3 billion of common stock over time. The company says it plans to use the proceeds for future growth initiatives, including potential acquisitions, as well as general corporate and working capital purposes.

Now, Rocket Lab isn't exactly strapped for cash. As of March 31, it reported more than $2 billion in total liquidity, including about $1.21 billion in cash and cash equivalents. But building rockets and spacecraft is a capital-intensive business — the company's Electron and Neutron launch vehicles don't come cheap. And with the stock up 433% over the past year, it's a pretty good time to raise money if you need it.

Still, the market doesn't love the idea of dilution, and shares were down 4.17% to $128.68 on Thursday.

SpaceX IPO: The Elephant in the Room

Rocket Lab's financing news comes just as its main competitor, SpaceX, filed for its own IPO — and it's a doozy. SpaceX could seek a valuation of nearly $1.75 trillion, potentially making it the largest public offering ever. Elon Musk's company reported $18.7 billion in revenue in 2025, though it also posted a $4.9 billion loss. Starlink generated $11.4 billion in revenue, SpaceX's launch business contributed $4 billion, and xAI added $3.2 billion.

Musk will retain 85.1% combined voting power after the IPO, according to the filing, which also highlighted asteroid mining plans and major NASA and U.S. Space Force contracts.

For Rocket Lab, the SpaceX IPO is a double-edged sword. On one hand, it draws attention to the space sector and could lift all boats. On the other, it reminds investors that Rocket Lab is competing with a company that has vastly more resources and a nearly trillion-dollar valuation.

Technical Check: Overbought and Below the EMA

Rocket Lab's stock has had an incredible run — up 433% over the past 12 months. But the technicals are starting to flash some warning signs.

The Relative Strength Index (RSI) is at 72.21, which means the stock is in overbought territory. That doesn't guarantee a pullback, but it suggests the rally might be getting a bit stretched. The stock is trading about 17.5% below its 20-day exponential moving average (EMA) of $106.68, indicating potential resistance at that level.

On the upside, the key resistance level is $138.38 — the 52-week high. That's a psychological barrier for traders. On the downside, the 20-day simple moving average (SMA) at $100.02 is a critical support level. If the stock drops below that, it could signal a shift in momentum.

Earnings Preview and Analyst Views

Rocket Lab's next financial update is expected around August 6, 2026. Analysts are looking for a loss of 8 cents per share, improving from a loss of 13 cents a year ago. Revenue is expected to come in at $230.16 million, up from $144.50 million.

The stock carries a Buy rating from analysts, with an average price target of $70.30 — which is actually well below the current price. That's a bit unusual, but it reflects the fact that the stock has run up faster than analysts have updated their targets. Recent analyst moves include BTIG initiating with a Hold on May 12, Deutsche Bank raising its target to $120 with a Buy on May 12, and Needham also raising its target to $120 with a Buy on May 11.

So, is the $3 billion offering a sign of confidence or desperation? Probably a bit of both. Rocket Lab is betting big on its future, and it's raising capital while the getting is good. But with SpaceX looming large and the stock already priced for perfection, investors will be watching closely.